BTL, a global leader in medical and aesthetic innovation, announces the launch of EMFACE® Eye, the first non-invasive procedure designed to reverse under-eye aging by restoring muscle tone and soft tissue support at its foundation.

This launch comes as EMFACE surpasses one million treatments globally, making it the fastest-growing facial aesthetic technology to date. It follows a record-breaking Q1 2025, with 70% sales growth in North America, underscoring the momentum behind the brand and its cutting-edge portfolio.

"The response to EMFACE has been phenomenal," said David Chmel, CEO of BTL Industries. "Reaching the one million treatment mark and reporting our strongest Q1 in history is a testament to the power of BTL innovation - and the trust our providers place in us. With EMFACE Eye, we're once again pushing the boundaries of what's possible in non-invasive aesthetics."

EMFACE Eye addresses one of the most delicate, and previously hard-to-treat, areas: under-eye region. While traditional approaches have often relied on injectables or surgery to reduce puffiness, dark circles, and hollowness, EMFACE Eye offers a breakthrough complement. It tones the lower orbicularis oculi muscle, lifts soft tissue, and enhances periorbital support.

In a quick 20-minute, needle-free procedure, patients experience an average reduction of 1.4mL in eye bag volume, a 28% reduction in crow's feet, and a 64% decrease in dark circles. These clinically backed results require no downtime, making it a breakthrough for both providers and patients alike.

Dr. Melanie Palm, M.D., MBA, a respected cosmetic dermatologist in Solana Beach, CA, praised the advancement:

"As a cosmetic dermatologist with a sizeable injectable practice, this is exactly what I've been waiting for. The results include noticeable brightening of the under-eye and buttressing of the infraorbital fat pad, significantly reducing fat pseudo-herniation."

"Emface restores structure and function to the facial anatomy in the most natural way, so we can count on superior results that drive high patient satisfaction."

With the addition of Eye applicators, the EMFACE platform now enables full-face balancing across all anatomical thirds—from forehead lifting to jawline sculpting to under-eye enhancement. The platform supports a comprehensive, layered approach that pairs seamlessly with injectable treatments to deliver natural, harmonious result. 

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes , EMSCULPT NEO®, EMFACE®, EXION™, EXOMIND™, EMSELLA®, and others.

For more information, visit www.bodybybtl.com.

Media Contact – samantha@samanthaslaven.com

EMFACE, the revolutionary non-invasive facial treatment, has reached an extraordinary milestone—becoming the fastest procedure of its kind to surpass 1 million treatments worldwide in just under two years. This achievement cements EMFACE as the leading non-invasive facial procedure uniquely designed to treat both the skin and underlying muscles for a more youthful, lifted appearance.

Developed by BTL, a global leader in medical technology, EMFACE transformed the industry in 2022 as the first operator-independent procedure to non-invasively target facial muscles while simultaneously improving skin quality.

"The ability to stimulate elevator muscles allows us to lift facial features from within—something that was never possible before with injectables or traditional energy-based devices," said Dr. Yael Halaas, a facial plastic surgeon from NYC, USA.

With no needles, downtime, or discomfort, EMFACE has gained widespread recognition among both medical professionals and patients, driving its rapid adoption across the globe.

Innovation at the Forefront of Success

Over the past year, EMFACE has expanded its capabilities with the introduction of specialized submental and under-eye applicators, making the treatment even more versatile. The latest eye applicators received overwhelmingly positive feedback from attending medical experts upon their launch at the IMCAS World Conference in Paris in January 2025.

"EMFACE isn't just a procedure—it's a facial multiplatform that allows us to treat different areas based on each patient's unique needs. It's a game-changer for anyone looking for natural-looking facial rejuvenation," added Dr. Kyungkook Hong, a board-certified dermatologist from Seoul, Korea.

Global Expansion and Industry Impact

EMFACE continues to gain momentum, with more practitioners integrating it into their treatment offerings. Its ability to complement injectables makes it a key component of comprehensive facial rejuvenation plans, providing patients with non-invasive solution for enhanced results.

"Reaching 1 million treatments in just two years is a testament to EMFACE's groundbreaking technology and the value it brings to medical professionals," said Tomas Schwarz, CEO of BTL. "We remain committed to expanding this platform and further advancing non-invasive facial treatments in the years ahead."

For more information about EMFACE and its revolutionary technology, visit www.emface.com.

About BTL

Founded in 1993, BTL has grown to become one of the world's leading medical equipment manufacturers. With 500+ engineers and 3,000+ employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including intimate health and mental wellness. Among other brands, BTL's products include EMSCULPT NEO^®, EMFACE^®, EXION™, EMSELLA^®, EXOMIND™ as well as their proprietary HIFEM^®, HIFES™ and EXOTMS™ procedures. Please visit www.btlaesthetics.com for additional information.

BTL, a global leader in aesthetic, wellness and longevity technologies, is thrilled to announce a new partnership with Nava Health, a premier provider of integrative holistic health and wellness solutions. This collaboration brings BTL's cutting-edge devices—Emsculpt Neo, Emsella, Emface, and Exion—to Nava Health's national network of health and wellness centers.

The partnership reflects a shared commitment to enhancing lives through advanced, results-driven technologies and personalized care. BTL's innovative offerings perfectly complement Nava Health's medical weight loss programs, hormone replacement therapy, functional nutrition, and regeneration services. Together, the two companies provide a seamless integration of wellness, aesthetics, and longevity.

"Nava Health is dedicated to providing holistic solutions that help people look and feel their best," said Alexis Gaus, Director of Aesthetics. "Integrating BTL's groundbreaking devices allows us to expand our offerings and provide our clients with effective, non-invasive treatments for body sculpting, facial rejuvenation, pelvic health, and overall wellness. This partnership is a natural fit for our mission."

BTL's devices are renowned for their advanced technology and proven results:

• Emsculpt Neo: Combines HIFEM+ and radiofrequency to reduce fat and build muscle in a single treatment, making it a perfect complement to Nava's medical weight loss solutions.
• Emsella: Revolutionizes pelvic floor health with non-invasive electromagnetic stimulation.
• Emface: Offers a needle-free solution for facial rejuvenation by improving muscle tone and skin quality.
• Exion: Delivers powerful results for improved skin tone and texture with unmatched versatility.

"We're excited to partner with Nava Health, a leader in holistic health and wellness," said Nathan Lanham, Director of National Accounts at BTL. "This collaboration underscores our shared dedication to innovation and delivering life-changing results for clients. Nava Health's expertise and reach will help bring the benefits of Emsculpt Neo, Emsella, Emface, and Exion to even more people across the country. Together, we are redefining wellness, aesthetics, and longevity."

With this partnership, Nava Health clients will now have access to cutting-edge technologies that align with their health and wellness goals, ensuring a transformative experience that goes beyond aesthetics.

For more information about BTL and Nava Health, please visit www.bodybybtl.com and www.navacenter.com.

About BTL
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO^®, EMFACE^®, EXION^®, EMSELLA^®, and others. For more information, visit www.bodybybtl.com

About Nava Health
Nava Health is a leading provider of integrative holistic health and wellness solutions, specializing in medical weight loss, functional medicine, hormone therapy, and regenerative treatments. With a mission to help people feel their best at every stage of life, Nava Health delivers personalized care through an integrative approach.

BTL, the innovator in medical and aesthetic technologies, is thrilled to introduce the EXOMIND, powered by ExoTMS technology - a state-of-the-art, non-invasive brain stimulation treatment designed to improve mental and emotional well-being.

EXOMIND is FDA-cleared for depression in the United States, and also approved by Health Canada and CE-marked for treating depression, anxiety symptoms, obsessive-compulsive disorder and excessive eating disorders.

"EXOMIND technology demonstrates our commitment to wellness by delivering natural, innovative solutions that empower individuals to reach their full potential," emphasized Filip Donner, Company's director. He continued, "This patient-friendly therapy aligns with our vision of promoting holistic health. Unlike conventional treatments, it provides a natural approach to mental wellness, fostering brain resilience without the side effects often associated with pharmaceuticals."

"Our record-breaking Q4, with over $220 million in global sales, is a testament to the growing demand for BTL's cutting-edge solutions," Donner added. "This achievement affirms the trust and confidence customers place in our technologies."

EXOMIND offers a pioneering treatment that appeals to patients seeking seamless, drug-free alternatives. In clinical studies, patients appreciate EXOMIND's  comfortable, walk-in, walk-out sessions lasting under 30 minutes. The device's ease of use allows for quick integration into medical practices, including family medicine and internal medicine practices.

"For my practice, EXOMIND has been a game-changer," said Dr. JD McCoy. "The device is easy to operate and gives our patients a unique offering they truly value." 

"The majority of my patients are on some form of antidepressant medication. With EXOMIND, we now offer an alternative that enhances patient well-being and provides them with the freedom to manage their mental wellness without relying solely on medication," added Dr. Yael Halaas.

About BTL
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EXOMIND™, EMSCULPT NEO®, EMFACE®, EXION™, EMSELLA®, and others. For more information, visit www.bodybybtl.com.

BTL, the innovator behind the Emsculpt Neo and Emsella wellness technologies, is thrilled to announce its partnership with Alo Wellness Clubs. This collaboration introduces BTL's groundbreaking health solutions to Alo's private wellness clubs in Los Angeles and New York City, giving members exclusive access to next-generation wellness experiences.

Elevating Wellness: Emsculpt Neo and Emsella at Alo Wellness Clubs

Through this partnership, Alo Wellness Clubs will now offer BTL's Emsculpt Neo, a device that combines muscle building and fat reduction using HIFEM+ technology, enhancing functional wellness alongside aesthetics. New protocols promote range of motion and muscle recovery, providing athletes and wellness enthusiasts an elevated health journey. Additionally, BTL's non-invasive Emsella technology will support core health with transformative pelvic floor therapy.

Exclusive Member Experiences and Collaborative Events

This collaboration will feature unique social media activations and wellness events, at Alo's flagship locations, enabling members to experience BTL's advanced technologies firsthand. A special edition of Emsculpt Neo, created in partnership with Alo, will also be launched, further enhancing the premium wellness offerings available to Alo members.

"Partnering with Alo Yoga Wellness Clubs is a win-win for us both," said John Ferris, Vice President of Marketing at BTL. "Together, we're creating an unparalleled wellness experience that aligns with our mission to elevate health and vitality within our communities. We're excited to bring Emsculpt Neo and Emsella to Alo's community, providing transformative wellness solutions to help members thrive."

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO^®, EMFACE^®, EXION™, EMSELLA^®, and others. For more information, visit www.bodybybtl.com

About Alo Yoga

Alo Yoga (Alo) is a Los Angeles-based premium lifestyle brand specializing in luxury activewear with a mission to spread mindful movement, inspire wellness and create community. Since launching in 2007, Alo has become a global leader in activewear design and its franchised fabrics. An acronym for Air, Land, and Ocean, Alo has a studio-to-street mentality that transcends fashion and goes beyond the mat. Alo is available online at www.aloyoga.com and Alo Sanctuaries worldwide.

Media Contact: btl@nouveaucommunications.com

As the prevalence of atrial fibrillation (AF) continues to rise, BTL has announced the successful treatment of the first six patients in the first-in-human feasibility study using a next-generation catheter system designed to streamline AF ablation. This new catheter technology is based on pulsed-field ablation (PFA), a cutting-edge approach that promises to make AF treatment safer, faster, and more effective. The system is undergoing clinical trial under the leadership of renowned experts in cardiology: Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital, NY, Dr. Petr Neuzil, Chief of Cardiology at Na Homolce Hospital, Prague and Dr. Štěpán Havránek, Head of Cardiac Electrophysiology at the General University Hospital in Prague.

BTL's upcoming technology features single-shot PVI for efficient pulmonary vein isolation and a versatile design that facilitates intuitive placement in diverse anatomies. This breakthrough enhances procedural reliability and consistency. The forthcoming ablation system is engineered to target all essential areas, extending beyond PVI, with a single device. Enhanced by high-density intracardiac signal acquisition for precise treatment, BTL's next-generation catheter aims to ensure optimal outcomes across different stages of AF. It will offer a comprehensive solution, supporting various ablation sizes from precise linear lesions to area ablations, thereby setting new benchmarks in AF ablation.

Dr. Vivek Reddy of Mount Sinai Hospital, New York, commented, "Our initial clinical results using the BTL catheter are very promising, and I look forward to the continued progress of clinical testing."

Dr. Petr Neužil, Principal Investigator at NNH Hospital in Prague, stated, "I have closely collaborated with BTL in developing this system from its inception, and I am excited to see that the initial results align with the promising outcomes observed in preclinical studies. The first six patients we treated with the Easy Pulz™ catheter at Homolka Hospital, together with my colleague Professor Vivek Reddy, had safe, effective, and straightforward procedures. These early results suggest that this new pulse field technology is very promising, with a lot of potential to make treatments easier and better for our patients."

About BTL
Founded in 1993, BTL is a global leader in medical device innovation, offering advanced solutions across various medical specialties including cardiology, orthopedics, dermatology, and more. With over 300 patents and a team of more than 500 in-house engineers, BTL is dedicated to revolutionizing medical treatments through cutting-edge technology and scientific expertise.
Contact: easypulz.press@btlnet.com